Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Dri Healthcare Trust T.DHT.UN

Alternate Symbol(s):  DHTRF

DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term. Geographically, it has a presence... see more

TSX:DHT.UN - Post Discussion

Dri Healthcare Trust > Sale of its TZIELD™ Royalty Interest to Sanofi for US$210 M
View:
Post by Betteryear2 on Apr 27, 2023 7:20pm

Sale of its TZIELD™ Royalty Interest to Sanofi for US$210 M

– Transaction will allow DHT to redeploy capital into new deals generating compounding returns for unitholders –

TORONTOApril 27, 2023 /CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("the Trust") announces that its wholly-owned subsidiary has sold its royalty interest and milestone payment obligations in the worldwide sales of TZIELD™ to a subsidiary of Sanofi S.A. ("Sanofi") for US$210 million.

DRI Healthcare Trust Announces Sale of its TZIELD™ Royalty Interest to Sanofi for US$210 Million and Announces a US$20 Million Special Cash Distribution to Unitholders (newswire.ca)

Be the first to comment on this post